Dacomitinib OverviewDacomitinib (PF-00299804) is a drug candidate under development by Pfizer for the treatment of non-small-cell lung carcinoma (NSCLC). It is a selective and irreversible inhibitor of EGFR. Dacomitinib has advanced to several Phase III clinical trials. The Jan 2014 results of the first trials were disappointing, with a failure to meet the study goals. Additional Phase III trials are ongoing. In 201...
Read more Dacomitinib Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Dacomitinib
Recent Dacomitinib Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Tablet: 15mg, 30mg, 45mg
Other drugs which contain Dacomitinib or a similar ingredient: (1 result)
- VIZIMPRO Dacomitinib